Cancer Discov. 2013 Aug;3(8):833-4. doi: 10.1158/2159-8290.CD-ND2013-018. Epub 2013 Aug 1.
As significant increases in the costs of cancer drugs cause financial difficulties for many U.S. patients, some oncologists suggest that changes in pricing policies at the federal and state levels are inevitable.
随着癌症药物成本的显著增加,许多美国患者面临财务困难,一些肿瘤学家表示,联邦和州层面的定价政策改革不可避免。